What is metastatic triple-negative breast cancer (mTNBC)?

It is an aggressive breast cancer subtype lacking estrogen, progesterone, and HER2 receptors, accounting for about 15% of breast cancer cases.

How does the label expansion affect Gilead's revenue?

It is expected to boost revenue by opening a larger first-line market; Trodelvy sales were $1.2 billion in 2025.

Who are Trodelvy's competitors?

Main competitors are Keytruda (Merck) and Enhertu (AstraZeneca/Daiichi Sankyo).

Trodelvy Label Expansion Strengthens Gilead's Oncology Portfolio

Gilead Sciences received FDA approval to expand Trodelvy's label to include first-line treatment for metastatic triple-negative breast cancer (mTNBC), strengthening its oncology portfolio and competitive position.

July 6, 2026

2 min read

Source: Zacks

Gilead Sciences (GILD) announced FDA approval to expand the label of Trodelvy (sacituzumab govitecan) to include first-line treatment for metastatic triple-negative breast cancer (mTNBC). This approval opens a broader market for the drug, which was previously limited to later-line therapies.

The Product

Trodelvy is an antibody-drug conjugate (ADC) targeting Trop-2, a protein overexpressed in many solid tumors. Clinical trials showed improved progression-free survival in mTNBC patients.

Pricing and Availability

Gilead has not disclosed updated pricing, but the drug is expected to be priced at a premium. It will be immediately available in the U.S. market.

Competition

Trodelvy faces competition from Keytruda (Merck) and Enhertu (AstraZeneca/Daiichi Sankyo). The label expansion gives Gilead a competitive edge in the mTNBC space.

Potential Impact on the Company

The expansion is expected to boost Trodelvy's revenue, which reached $1.2 billion in 2025, and support Gilead's oncology strategy following several acquisitions.

Frequently Asked Questions

Trodelvy is an antibody-drug conjugate (ADC) targeting Trop-2, used for metastatic triple-negative breast cancer.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.